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Benzo[c]quinolizinium compounds (MPB) have been identiﬁed as dual activity
drugs: activator and corrector of CFTR (Derand 2001; Dormer 2001). Previous
studies suggest a direct interaction of the MPB compound with the c-term part
of NBD1 of CFTR (Norez 2008). We now performed a molecular dissection
of this putative pharmacological site by examining several CFTR mutants. We
studied G622 & G628, two highly conserved glycins in ABC transporters and
suspected to be located on the last b strand of the NBD1 (Callebaut, 2003). First we
constructed G622D and G628R. Western blot analysis showed a strong diminution
of mature C-band form for G622D compared to wt and no C-band for G628R.
However patch clamp analysis using whole cell conﬁguration revealed a linear
Cl− current stimulated by forskolin (Fsk) for both mutants. Current densities at
+40mV (respectively 36±4 pA/pF & 18±5 pA/pF) are reduced compared to wt
current density (82±9 pA/pF). In presence of miglustat, a CFTR corrector, G622D
current density (86±12 pA/pF) increased to a level similar to wt while the current
density of G628R (38±7 pA/pF) although augmented, remains reduced compared to
wt. Interestingly no activation of these mutated channels was recorded in presence
of MPBs. A third mutation located downstream the b strand (H620Q) results in a
CFTR channel with an increased Cl− transport activity (125±19 pA/pF at +40mV
with Fsk). This CFTR mutant was activated by MPBs. All these results suggest that
this domain has a folding pattern essential for trafﬁcking but also for activation of
CFTR channels. G622D & G628R mutants but not H620Q are refractory to MPB
action, indicating that the last b strand of the NBD1 is likely to play a critical role
in the MPB-CFTR interaction.
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CFTR functions as a cAMP-activated chloride (Cl−) channel, regulated by protein-
protein interactions. The extend of which CFTR is regulated by these interactions
remains unknown. Nevertheless, we previously showed that annexin V (anxA5)
binds to both the normal CFTR and the F508del-CFTR and that its overexpression
increases F508del-CFTR function.
Our aim is to increase anxA5 expression by a drug in F508del-CFTR expressing
cells. Because GnRH is known to increase anxA5 expression, we tested its effects
upon F508del-CFTR function.
We showed using western blottings that GnRH Receptors are expressed in non-
polarized A549 cells expressing either wild-type CFTR or F508del-CFTR, and
in polarized 16HBE and CFBE cells. We further treated these cells with GnRH
(10−9 M) and assessed anxA5 expression by western blotting. The Cl− channel
function of CFTR was studied by SPQ and patch-clamp experiments. The effect
of GnRH upon the membrane localization of CFTR is now under investigation.
Finally, immunohistochemistry study of GnRH Receptor was performed in human
airways to check potential clinical use of the hormone.
Beside the GnRH Receptor expression, we showed that anxA5 expression is
increased after 1 h incubation with GnRH. SPQ and patch-clamp results indicate
that GnRH increases the F508del-CFTR activity. Immunostaining shows that GnRH
Receptor is present in human airways.
In conclusion, GnRH treatment leads to a signiﬁcant anxA5 overexpression and
subsequently to an increased function of F508del-CFTR. Improvement of CFTR
trafﬁcking to the cell surface is under investigation. We propose that GnRH is a
potential therapeutic in cystic ﬁbrosis.
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Cystic ﬁbrosis is mainly caused by mutations interfering with the biosynthetic
folding of the CFTR protein. The aim of this study was to ﬁnd proteins able
to interact with CFTR and modify its processing. We have identiﬁed COMMD1 as
a new CFTR partner. COMMD1 is a regulator of copper homeostasis and sodium
uptake through interaction with ENaC, as well as the prototype of a new protein
family that plays a role in inhibiting NF-úB signalling
Co-immunoprecipitation experiments showed that COMMD1 associates with en-
dogenous CFTR in HT29 cells and with F508del-CFTR in heterologously ex-
pressing epithelial cells. COMMD1 sub-cellular distribution is both nuclear and
cytoplasmic, and more precisely in vesicular cytoplasmic compartments, as assessed
by immunocytochemical microscopy. Further studies showed COMMD1 partial
codistribution with an early endosomal compartments (TfR).
COMMD1 is not involved in CFTR processing (C band) but wt-CFTR cell surface
expression was half-reduced when COMMD1 expression was silenced. Unlike
F508del-CFTR in temperature rescue, COMMD1 over-expression increased 15%
wt-CFTR cell surface expression. Assessment of CFTR ubiquitination showed
that COMMD1 over-expression strongly decreased CFTR ubiquitination therefore
increasing CFTR cell surface expression. Finally, these data indicate that COMMD1
vesicular compartment is involved in CFTR trafﬁcking through inhibition of CFTR
ubiquitination.
Understanding how COMMD1 modulation modiﬁes transepithelial transport and
inﬂammation in CF versus non CF cells should give new therapeutic clues to reduce
exacerbated inﬂammation and improve ﬂuid secretion in CF patients.
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site´s de Paris and Vaincre La Mucoviscidose.
72 Estrogen and phytoestrogens increase the CFTR and F508del
CFTR expression and function
N. Hamdaoui1,2, D.L. Vieu1,2, M. Baudouin-Legros1,2, A. Edelman1,2,
G. Planelles1,2. 1U845, Inserm, Paris, France; 2Descartes Paris5 University,
Paris, France
A major challenge faced by cystic ﬁbrosis (CF) research is to address functional
F508del-CFTR to the plasma membrane in which it may function as a cAMP-
activated Cl− channel defective in >70% of CF patients.
It has been recently reported that 17b-estradiol (17b-E)rescues F508del-CFTR in a
bronchiolar cell line (Fanelli et al, Biol Cell. 2008 10:39).
Our aim was to investigate the effect of 17beta-E and other estrogenic derivatives in
human cell lines expressing CFTR/F508del-CFTR. Experiments were performed on
the pancreatic cell line CFPAC expressing F508del-CFTR, and on the breast cancer
cell line MCF7 expressing CFTR. Cells were treated for 2 or 18 h with various
natural or synthetic estrogenic compounds. CFTR expression and localization
was appreciated by immunoblot (IB), and confocal cyto-immunochemistry. CFTR
function was assessed using a video-imaging system to monitor the ﬂuorescence
of cells loaded with 6-methoxy-N-3-sulfopropylquinolinium (SPQ), an anionic-
sensitive dye. CFTR was activated by exposing SPQ-loaded cells to a PKA-activated
cocktail.
In both cell lines, the IB analysis showed that all the tested compounds (including
natural phyto-estrogens) increased in a time-dependent manner CFTR total expres-
sion. Initial analysis of dose-response curves seem to be as inverted U-shape. CFTR
immunolocalization by Mab 24−1 antibody showed the increase of cytoplasmic
expression followed by increased membrane expression. In F508del-CFTR cells,
the presence of functional F508del-CFTR was demonstrated by SPQ functional
assay.
Taken together, these experiments suggest that other estrogenic compounds than
17bE and its derivatives may be of interest in CF therapy.
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